Phase II dose escalation study of caspofungin for invasive Aspergillosis.

1st Department of Internal Medicine, University Hospital of Cologne, Kerpener Str 62, 50937 Cologne, Germany.
Antimicrobial Agents and Chemotherapy (Impact Factor: 4.57). 09/2011; 55(12):5798-803. DOI: 10.1128/AAC.05134-11
Source: PubMed

ABSTRACT Our objective was to evaluate the maximum tolerated dose of caspofungin for invasive aspergillosis (IA). The safety and pharmacokinetics of escalating dosages of caspofungin were investigated in IA. Eight patients each received caspofungin 70, 100, 150, or 200 mg once a day (QD). Dose-limiting toxicity (DLT) was defined as the same non-hematological treatment-related adverse event of grade ≥ 4 in 2 of 8 patients or ≥ 3 in 4 of 8 patients in a cohort. A total of 46 patients (median age, 61 years; 21 female; 89% with hematological malignancies) received caspofungin (9, 8, 9, and 20 patients in the 70-, 100-, 150-, and 200-mg cohorts) for a median of 24.5 days. Plasma pharmacokinetics were linear across the investigated dosages and followed a two-compartment model, with weight as the covariate on clearance and sex as the covariate on central volume of distribution. Simulated peak plasma concentrations at steady state ranged from 14.2 to 40.6 mg/liter (28%), trough concentrations from 4.1 to 11.8 mg/liter (58%), and area under the concentration-time curve from 175 to 500 mg/liter/h (32%) (geometric mean, geometric coefficient of variation). Treatment was well tolerated without dose-limiting toxicity. The rate of complete or partial responses was 54.3%, and the overall mortality at 12-week follow-up was 28.3%. In first-line treatment of invasive aspergillosis, daily doses of up to 200 mg caspofungin were well tolerated and the maximum tolerated dose was not reached. Pharmacokinetics was linear. Response rates were similar to those previously reported for voriconazole and liposomal amphotericin.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Killing rates (K) of 1-32 mg ml-1 caspofungin was determined in RPMI-1640 and in 50% serum using time-kill methodology against three C. krusei (MIC of all three isolates 0.25 mg ml-1 in RPMI-1640 and 2 mg ml-1 in serum) and three C. inconspicua clinical isolates (MIC ranges 0.06-0.12 mg ml-1 in RPMI-1640 and 0.25-0.5 mg ml-1 in serum), against C. krusei ATCC 6258 and against one C. krusei isolate resistant to echinocandins (MIC 8 mg ml-1 in RPMI-1640 and 32 mg ml-1 in serum). In RPMI-1640, the highest mean K values were observed at 4 (-1.05 h-1) and 16 (-0.27 h-1) mg ml-1 caspofungin for C. krusei and C. inconspicua clinical isolates, respectively. In 50% serum, mean K value ranges at 1-32 and 4-32 mg ml-1 concentrations for C. inconspicua and C. krusei were -1.12 to -1.44 h-1 and -0.42 to -0.57, respectively. While K values against C. krusei in RPMI-1640 and 50% serum were comparable, serum significantly increased the killing rate against C. inconspicua (P<0.0003 for all tested concentrations). In a neutropenic murine model daily 1, 2, 3, 5 and 15 mg/kg caspofungin significantly decreased the fungal tissue burden of C. inconspicua in the kidneys (P<0.05-0.001). Against C. krusei, doses 3, 5 and 15 mg/kg were effective (P<0.05-0.01). All effective doses were comparably efficacious for both species. Fifteen mg/kg caspofungin was effective even against the echinocandin resistant C. krusei isolate. In 50% serum, killing was concentration independent at effective concentrations (≥4 mg ml-1 and ≥1 mg ml-1 for C. krusei and C. inconspicua, respectively), suggesting that the efficacy of dose escalation is questionable. These in vitro results were also supported by the murine model.
    Journal of Medical Microbiology 11/2013; · 2.30 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objectives. Caspofungin (CAS) is approved for second line management of proven or probable invasive aspergillosis at a dose of 50 mg once daily (QD). Preclinical and limited clinical data support the concept of dose-dependent antifungal efficacy of CAS with preservation of its favourable safety profile. Little is known, however, about the pharmacokinetics of higher doses of CAS in patients.Methods. In a formal multicentre phase II dose escalation study, CAS was administered as 2 h infusion at doses ranging from 70 to 200 mg QD. CAS PK sampling (n=468 samples) was performed on day 1 and at peak and trough time points at days 4, 7, 14, and 28 (70 mg: 9, 100 mg: 8, 150 mg: 9, 200 mg: 20, total: 46 patients). Drug concentrations in plasma were measured by liquid chromatography tandem mass spectroscopy. Population pharmacokinetic analysis (PopPK) was performed using NONMEM 7 software. Model evaluation was performed using bootstrap analysis, prediction corrected visual predictive check (pcVPC) as well as standardized visual predictive check (SVPC).Results. The four investigated dose levels showed no difference in log-transformed dose-normalised trough levels of CAS (ANOVA). CAS concentration data fitted best to a two-compartment model with proportional error model, interindividual variability (IIV) on clearance (CL), central (V1) and peripheral (V2) volume of distribution, covariance on CL and V1, interoccasion variability (IOV) on CL and body weight as covariate on CL and V1 (CL 0.411 L/h ± 29 %, IOV on CL: 16 %, V1: 5.785 L ± 29 %, Q: 0.843 L/h, V2: 6.53 L ± 67 %). None of the other examined covariates (dose level, gender, age, serum bilirubin, creatinine clearance) improved the model further. Bootstrap results showed robustness of the final PopPK model. pcVPC and SVPC showed its predictability and further confirmed linear PK of CAS in the dosage range of 70 to 200 mg QD. Based on the final model, simulated peak plasma levels at steady state ranged from 13.8 to 39.4 mg/L (31 %), trough levels from 4.2 to 12.0 mg/L (49 %), and area under the concentration-time curve from 170 to 487 mg*h/L (34 %) for the dosage range of 70 to 200 mg QD (geometric mean, geometric coefficient of variation).Conclusion. CAS showed linear PK across the investigated dosage range of 70 to 200 mg QD. Drug exposure in the present study population was comparable to those in other populations.
    Antimicrobial Agents and Chemotherapy 01/2013; · 4.57 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Invasive fungal infections (IFIs) pose significant morbidity and are often life-threatening to many high-risk patients. Timely diagnosis and treatment of these infections with optimal therapy is imperative. Areas covered: Advances have been made in diagnostic biomarkers such as peptide nucleic acid fluorescent in situ hybridization, β-D-glucan and galactomannan, although more research is needed in this area to assist with both diagnosis and monitoring for improvement of IFI management. Novel antifungal agents (azole antifungals and echinocandins) are being investigated that have activity against Candida spp. and Aspergillus spp. Optimizing the pharmacodynamics (PD) of our current antifungal therapies through such strategies as continuous infusion of amphotericin B and dose escalation of echinocandins and liposomal formulations of amphotericin B have also been investigated with mixed results. Therapeutic drug monitoring (TDM) shows promise as evident from data with such agents as flucytosine, itraconazole, voriconazole and posaconazole. Expert opinion: The goal for the future of biomarkers in IFIs will be to have excellent sensitivity and specificity to ideally identify a particular fungus causing the infection or eliminate its existence to prevent unnecessary costs, resistance and antifungal usage. In addition, further developments of new antifungals are needed and judicious use of the current regimens needs to be optimized through antifungal PD properties and TDM.
    Expert Opinion on Pharmacotherapy 09/2013; · 2.86 Impact Factor

Full-text (2 Sources)

Available from
Jun 1, 2014